Joseph Keenan
About Joseph Keenan
Joseph Keenan is a reporter known for his coverage of significant health sector developments, including vaccine production and FDA regulatory actions.
Reporter Joseph Keenan
Joseph Keenan is a reporter known for his work on significant healthcare and pharmaceutical topics. His reporting often covers major contracts, regulatory actions, and public health initiatives. His work has included detailed coverage of the U.S. Department of Defense's contracts, FDA regulatory actions, and CDC campaigns.
Contract Reporting on Emergent BioSolutions and BioThrax Vaccine
Joseph Keenan reported on Emergent BioSolutions being awarded a $235.8 million contract to supply the anthrax vaccine BioThrax to various branches of the military. This significant contract underscores the ongoing efforts to bolster biodefense capabilities amid biological threats. His coverage provides detailed insights into the financial and strategic implications of such contracts.
Insights on Vaccine Misinformation and Scientific Evidence
In response to FDA Commissioner Robert Califf's call for more plain-language scientific evidence to combat vaccine misinformation, Joseph Keenan highlighted the importance of clear and accessible communication in public health. The emphasis on combating misinformation reflects a broader commitment to enhancing public trust and understanding of vaccines.
FDA Regulatory Actions and Manufacturing Deviations
Joseph Keenan reported on the FDA's warning letter to Chinese API maker Sichuan Deebio for significant deviations in manufacturing operations. Additionally, he covered the FDA's issuance of a Complete Response Letter (CRL) to Zealand Pharma for its hypoglycemia drug due to manufacturing problems. His reporting tracks the critical role of regulatory oversight in ensuring pharmaceutical quality and safety.
COVID-19 Vaccine Manufacturing Adjustments by Moderna
Joseph Keenan reported on Moderna's consideration to scale back COVID-19 vaccine manufacturing in response to falling demand. This report sheds light on the shifting dynamics of vaccine production and demand during the pandemic, offering insights into the logistical and strategic decisions faced by vaccine manufacturers.
CDC's 'Wild to Mild' Campaign
Joseph Keenan covered the CDC's 'Wild to Mild' campaign aimed at reversing falling flu vaccine use in key demographic groups. The campaign's objective is to increase vaccination rates by simplifying the decision-making process for the public, reflecting broader public health strategies to improve vaccine uptake.
Japan's Funding for mRNA Vaccine Manufacturing
In his reporting, Joseph Keenan covered Japan's award of $115 million to an Arcturus Therapeutics joint venture to boost mRNA vaccine manufacturing. This coverage highlights international efforts to enhance vaccine production capacities amid evolving infectious disease challenges.